<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02414919</url>
  </required_header>
  <id_info>
    <org_study_id>17714</org_study_id>
    <nct_id>NCT02414919</nct_id>
  </id_info>
  <brief_title>Duration of Use of Highly Effective Reversible Contraception</brief_title>
  <official_title>Real-world Duration of Use for Highly Effective Reversible Contraception (HERC): A Retrospective Review</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the proportion of women who use HERC for ≥2 years of duration
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2015</start_date>
  <completion_date type="Actual">March 28, 2016</completion_date>
  <primary_completion_date type="Actual">March 28, 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of women who use HERC</measure>
    <time_frame>2 years post-HERC initiation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of real world use of three different HERC devices</measure>
    <time_frame>2 years post-HERC initiation</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Difference in patient characteristics of women who chose different HERC devices</measure>
    <time_frame>2 years post-HERC initiation</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of HERC used for ≥3 years of duration</measure>
    <time_frame>≥3 years post-HERC initiation</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Model the predictors of ≥3 years of duration</measure>
    <time_frame>≥3 years post-HERC initiation</time_frame>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">13880</enrollment>
  <condition>Pregnancy</condition>
  <arm_group>
    <arm_group_label>HERC</arm_group_label>
    <description>Women who had an insertion of HERC (Mirena IUD, ParaGard IUD, Implanon or Nexplanon)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mirena (Levonorgestrel IUS, BAY86-5028)</intervention_name>
    <description>Levonorgestrel-releasing intrauterine device 20 mcg/day</description>
    <arm_group_label>HERC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ParaGard</intervention_name>
    <description>Copper T380A</description>
    <arm_group_label>HERC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Implanon/Nexplanon</intervention_name>
    <description>Etonorgestrel contraceptive implant</description>
    <arm_group_label>HERC</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Women who had an IUD or contraceptive implant inserted at the University of Utah healthcare
        system
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -Women who had an IUD or contraceptive implant inserted and removed within the University
        of Utah from January 1, 2004 to October 31, 2012
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>44 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Salt Lake</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <reference>
    <citation>Sanders J, Turok D, Gawron L, Law A, Wen L, Lynen R. Continuation of Long-Acting Reversible Contraception at Two Years in a University Healthcare Setting: A Retrospective Review. JMCP 2016;22(4a):S126</citation>
  </reference>
  <results_reference>
    <citation>Sanders JN, Turok DK, Gawron LM, Law A, Wen L, Lynen R. Two-year continuation of intrauterine devices and contraceptive implants in a mixed-payer setting: a retrospective review. Am J Obstet Gynecol. 2017 Jun;216(6):590.e1-590.e8. doi: 10.1016/j.ajog.2017.02.003. Epub 2017 Feb 8.</citation>
    <PMID>28188772</PMID>
  </results_reference>
  <results_reference>
    <citation>Sanders J, Turok D, Gawron L, Law A, Wen L, Lynen R. Three-Year Continuation of Long-Acting Reversible Contraceptive methods in a Mixed-Payer Health Care Setting: A Retrospective Review. Contraception 2016;94:405-406.</citation>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 8, 2015</study_first_submitted>
  <study_first_submitted_qc>April 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2015</study_first_posted>
  <last_update_submitted>March 14, 2017</last_update_submitted>
  <last_update_submitted_qc>March 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levonorgestrel</mesh_term>
    <mesh_term>Etonogestrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

